Last updated: April 24, 2026
Who Supplies Uridine Triacetate for Pharmaceutical Use?
Uridine triacetate (UTAT; also referred to as uridine triacetate) is a small-molecule API and precursor salt/compound that is sourced through established chemical and API manufacturing supply chains. In practice, sourcing splits into two lanes: (1) finished API supply under GMP and (2) contract manufacturing for batches from established chemical intermediates.
Because supplier identity depends on registration status, GMP capability, and whether the buyer needs R&D quantities or commercial API, the supplier universe is best expressed as procurement-ready entities by role (API manufacturer vs. chemical intermediate maker), plus the procurement artifacts buyers typically require (CoA, GMP, DMF references, and regulatory filing support).
Which supplier types sell uridine triacetate?
- GMP API manufacturers
Sell uridine triacetate as an API with documentation suitable for IND and NDA/ANDA workflows (typically CoA per batch, GMP letters, and tech pack support).
- Contract manufacturing organizations (CMOs) for API
Provide synthesis and scale-up under quality agreements and batch records, sometimes leveraging supplier intermediates.
- Chemical suppliers of the active/intermediate
Offer lower-tier chemical supply for research-grade work; some can convert to GMP supply depending on client spend and regulatory readiness.
How do pharma buyers shortlist uridine triacetate suppliers?
Use these hard filters to avoid non-compliant sourcing outcomes:
- GMP status: API manufactured under GMP with batch traceability and validated analytics.
- Regulatory dossier support: DMF/ASMF availability or bridging support for your regulatory strategy.
- Analytical package: HPLC/UPLC methods, related substances control, polymorph/hydrate confirmation if relevant, and impurity profiling.
- Packaging and stability: validated container-closure system plus CoA shelf-life statement and stability protocol.
- Scale capability: milligram-to-gram for early development, then multi-kg or commercial lots.
What is the practical supplier landscape for uridine triacetate?
API and development supply: who appears in commercial sourcing workflows?
Uridine triacetate supply for pharma typically comes from:
- Specialty API manufacturers with experience in nucleoside/uridine derivative chemistry and acetylation chemistry.
- Chemical CDMOs with capability for controlled acylation (acetate formation) and impurity control to meet regulatory specs.
In real procurement, buyers usually do not purchase “through brokers only.” They request:
- GMP manufacturing confirmation (site + process)
- batch CoA template
- analytical method summaries
- stability data package
- right to reference filings (if using DMF/ASMF)
Supplier shortlisting checklist (procurement-ready)
What documentation should buyers demand before placing supply orders?
- CoA per batch (purity, related substances, assay, moisture if specified)
- GMP certificate for the manufacturing site (not just a general corporate GMP statement)
- Specification limits (assay range and all named/un-named impurities where applicable)
- Analytical method package (at minimum summary; in some cases full method transfer)
- Stability program and retest/shelf-life data
- Change control policy (process changes, impurity drift, source changes)
What quality/contract terms should be standard for API supply?
- Quality agreement with audit rights
- Material transfer agreement (if needed)
- Right to receive notification of deviations/out-of-spec events
- Data integrity commitments for batch records and QC
Commercial sourcing strategy by development stage
How sourcing differs for R&D vs. commercial
Early development (IND-enabling):
- Priority: fast lead time, method alignment, impurity profile readiness
- Typical supply path: development-grade GMP batches with tech transfer support
Clinical mid-stage and late-stage (Phase 2-3):
- Priority: batch-to-batch consistency, validated analytics, stability coverage
- Typical supply path: qualified GMP supply with dossier bridging support
Commercial (NDA/ANDA manufacturing):
- Priority: long-term cost, supply continuity, validated manufacturing process
- Typical supply path: long-term supply agreements with audit-backed compliance
Key Takeaways
- Uridine triacetate sourcing works through three practical channels: GMP API manufacturers, API CMOs, and chemical suppliers that may or may not support GMP/regulatory needs.
- The actionable supplier decision is driven by GMP status, regulatory dossier support (DMF/ASMF references), and an analytical and stability package that matches your filing and specification requirements.
- Procurement readiness depends on the documentation stack (CoA, GMP site evidence, method summaries, stability data, and change control terms), not on supplier identity alone.
FAQs
1) Is uridine triacetate typically supplied as GMP API?
Yes, for pharmaceutical use it is generally sourced as GMP-manufactured API with CoAs and batch traceability suitable for clinical or commercial manufacture.
2) What is the biggest sourcing risk with uridine triacetate?
The main risk is quality and regulatory mismatch (non-GMP supply, missing impurity controls, or insufficient stability and analytical documentation), which delays qualification.
3) Can chemical suppliers provide uridine triacetate for pharmaceutical development?
Some can, but the supply must be validated for GMP equivalence and supported with the regulatory documentation required by your development plan.
4) What regulatory artifacts matter when selecting an API supplier?
Look for DMF/ASMF availability or bridging support, plus batch records and quality documentation that integrate with your submission strategy.
5) How should buyers evaluate supplier scale capability for UTAT?
Match your demand forecast (kg range for late stage/commercial) to the supplier’s demonstrated batch size, yield, and impurity control capabilities.
Sources
[1] FDA. “Drug Master Files (DMF).” U.S. Food & Drug Administration. https://www.fda.gov/drugs/development-resources/drug-master-files-dmf
[2] EMA. “Procedural advice on submission of dossiers.” European Medicines Agency. https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/procedural-advice-submission-dossiers_en.pdf
[3] ICH. “Q7: Good Manufacturing Practice Guidance for Active Pharmaceutical Ingredients.” International Council for Harmonisation. https://database.ich.org/sites/default/files/Q7_R2_Addendum.pdf
[4] ICH. “Q3A(R2): Impurities in New Drug Substances.” International Council for Harmonisation. https://database.ich.org/sites/default/files/Q3A_R2_Guideline.pdf
[5] ICH. “Q1A(R2): Stability Testing of New Drug Substances and Products.” International Council for Harmonisation. https://database.ich.org/sites/default/files/Q1A%20R2%20Guideline.pdf
